Publication: Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants
Issued Date
2006-08-01
Resource Type
ISSN
00015792
Other identifier(s)
2-s2.0-33747439438
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Acta Haematologica. Vol.116, No.2 (2006), 114-119
Suggested Citation
C. U. Auewarakul, S. Huang, M. Yimyam, S. Boonmoh Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants. Acta Haematologica. Vol.116, No.2 (2006), 114-119. doi:10.1159/000093641 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/23660
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants
Author(s)
Other Contributor(s)
Abstract
Little evidence exists regarding the prognostic impact of the major BCR-ABL gene variants (e13a2 and e14a2) in chronic myeloid leukemia (CML) patients diagnosed and treated in the developing Asian countries. In this study, 139 Thai CML patients were followed for a median period of 3 years (range 18-43 months). Clinical presentations of both BCR-ABL gene variant groups (73% e14a2+ and 27% e13a2+) were similar, although e14a2+ patients tended to be older (42 vs. 37 years) and had higher white blood cell counts than e13a2+ patients. The majority of patients in both groups presented with Sokal stage 2-3 (score >0.8) and were categorized as Hasford's intermediate- to high-risk groups (score >780). All patients received oral chemotherapy and 13% underwent allogeneic stem cell transplantation. None received oral tyrosine kinase inhibitors. In the conventional chemotherapy group, the overall survival (OS) rate was slightly better in e14a2+ than in e13a2+ patients (p = n.s.). The median survival in e14a2+ and e13a2+ patients who did not receive stem cell transplantation was 49 and 33 months, respectively (p = n.s.). The type of blastic crisis in e14a2+ and e13a2+ patients was similar, being predominantly myeloid. In conclusion, CML patients in Thailand, despite being much younger, had a comparable OS with those in the Western countries, with no different OS between e14a2+ and e13a2+ patients. Future studies should focus on the impact of novel oral BCR-ABL tyrosine kinase inhibitors on the outcome of Thai CML patients with different BCR-ABL gene variants. Copyright © 2006 S. Karger AG.